BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating. The catalyst: the…


















